Trial reportFrontiers in endocrinology2025
Impact of the new EASO obesity definition on the detection of atheromatosis in subjects with low-to-moderate cardiovascular risk.
Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03228459 (Randomized Intervention Study to Assess the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease and Its Impact on Morbidity and Mortality), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Intervention Study to Assess the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease and Its Impact on Morbidity and Mortality: The ILERVAS Project
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traditional body mass index (BMI) does not adequately reflect adipose tissue distribution and associated cardiovascular (CV) risk. To improve risk stratification, the European Association for the Study of Obesity (EASO) proposes to extend the diagnosis of obesity to include individuals with a BMI of 25-30 kg/m², a waist-to-height ratio (WtHR) ≥0.5, and any obesity-related complication. Objective: To examine whether this new definition of obesity can better identify the presence of subclinical atheromatosis disease (SAD) in terms of arterial plaque burden compared to the classical BMI-based definition. Methods: A cross-sectional including 8,330 participants from the ILERVAS project (ClinicalTrials.gov Identifier: NCT03228459), aged 45-70 years with low-to-moderate CV risk and no previous CV disease, was included. Obesity was classified using traditional (BMI ≥ 30 kg/m²) and new definitions. Atherosclerosis was assessed through Doppler ultrasound of carotid and femoral arteries. Logistic regression models adjusted for cardiovascular risk factors were used to evaluate associations between obesity definitions and SAD. Results: The new definition increased obesity prevalence from 37.2% to 71.7%. It also revealed higher detection of atheromatous plaques (72.9% vs. 68.6%, Conclusion: The new obesity definition identifies more efficiently individuals at risk for atherosclerosis, especially in the femoral region, compared to the classic BMI definition. Further studies to assess the cost-effectiveness of this approach seem warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.